Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

Online First

FDA Oncology Update

Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion

FDA Oncology Update

FDA Accelerated the Approval of Akeega, First and Only Dual-Action Tablet for Metastatic Prostate Cancer With BRCA Mutation

FDA Oncology Update

FDA Granted Accelerated Approval to Elrexfio, a Bispecific BCMA-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM

FDA Oncology Update

Hepzato Kit FDA Approved as a Liver-Directed Treatment for Uveal Melanoma With Hepatic Metastases

FDA Oncology Update

FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM

JHOP - August 2023 Vol 13, No 4

Original Article

Effects of Vascular Endothelial Growth Factor Inhibitor–Induced Proteinuria on Treatment Course and Outcomes: Retrospective Analysis and Review of the Literature

Original Article

Effects of Levofloxacin Prophylaxis in Pediatric Patients With Acute Myeloid Leukemia, Relapsed Acute Lymphoblastic Leukemia, or Patients Undergoing Hematopoietic Stem Cell Transplant

Original Article

Duration of Response to PARP Inhibitors for Maintenance Treatment of Ovarian Cancer in Patients With Germline or Somatic HRD

Review Article

A Review of Clinical Data Among Biosimilars: Just How Similar Are They?

Practical Issues in Pharmacy Management

Impact of Pharmacist-Led Oral Chemotherapy Telehealth Clinic at a Community Cancer Center Using the TAMER Model

FDA Oncology Update

FDA Accelerated the Approval of Columvi for Selected Relapsed or Refractory Large B-Cell Lymphomas

Meeting Highlights

Zanidatamab Plus Docetaxel Shows Promising Antitumor Activity in Advanced HER2-Positive Breast Cancer

Prolonged Effectiveness With Tucatinib Plus Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer

Inetetamab Plus Camrelizumab and Utidelone Safe and Effective in Patients With HER2-Positive Metastatic Breast Cancer

FDA Oncology Update

Epkinly FDA Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

Polivy Received New Indication for First-Line Treatment of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma

Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation

Most Popular Articles

JHOP - August 2023 Vol 13, No 4 - Practical Issues in Pharmacy Management

Impact of Pharmacist-Led Oral Chemotherapy Telehealth Clinic at a Community Cancer Center Using the TAMER Model

JHOP - June 2023 Vol 13, No 3 - Practical Issues in Pharmacy Management

Clinical and Financial Impacts of an Ambulatory Oncology Pharmacist–Based Intravenous Chemotherapy Education and Follow-Up Program

JHOP - June 2023 Vol 13, No 3 - Original Article

Stopping Oral Chemotherapy Agents With a High Bleeding Risk Before and After Minor Surgical Procedures

JHOP - June 2023 Vol 13, No 3 - Original Article

Incidence of Infusion-Related Reactions With Pertuzumab and Ado-Trastuzumab Emtansine: A Retrospective Study